Form 4: Tivic Health Systems Insider Transaction: Chief Scientific Officer Acquires Stock Options

Blake Gurfein, Chief Scientific Officer of Tivic Health Systems, acquired 10,000 employee stock options on March 12, 2024, at an exercise price of $1.34.

Summary

• On March 12, 2024, Blake Gurfein, the Chief Scientific Officer of Tivic Health Systems, acquired 10,000 employee stock options.
• The exercise price for these options is $1.34 per share.
• The options vest over a period, with 50% vesting on the first anniversary of the grant date and the remaining 50% vesting in 12 equal monthly installments thereafter.
• The options expire on March 11, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction. The grant of options to a key executive is generally a positive sign, but this is standard practice.

Positives

• The acquisition of stock options by a key executive like the Chief Scientific Officer can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, reflecting a common practice of granting stock options to company executives as part of their compensation package. It's typical for companies, especially in the tech and biotech sectors, to use stock options to incentivize and retain key personnel.

Stakeholder Impact

• The granting of stock options to executives can align their interests with those of shareholders, potentially driving long-term value creation.

Key Dates

Keywords

Tivic Health Systems, insider trading, stock options, Form 4, Blake Gurfein, Chief Scientific Officer, equity, transaction